Cite
HARVARD Citation
Remák, E. et al. (n.d.). Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data. European journal of cancer. pp. S18-. [Online].